BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Australia’s Clarity Pharmaceuticals Expands Pipeline with Novel FAP-Targeted Radiopharmaceutical

Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of...

December 19, 2024 | News

Australia’s Cartherics Secures $300K G-Rex Grant to Advance Manufacturing of Allo CAR-iNK Cells for Ovarian Cancer Trials

- Cartherics has received a US$300K G-Rex grant to support its ‘in house’ manufacturing program- Funding will enable Cartherics to generate cru...

December 18, 2024 | News

SK bioscience to Launch Phase 1/2 Trials for First mRNA Vaccine Candidate in Australia

SK bioscience’s first mRNA vaccine candidate is expected to enter clinical trials in Australia in February 2025, with interim results expected by 2...

December 13, 2024 | News

Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria

The Southern Hemisphere’s only mRNA manufacturing facility has officially opened in Victoria, marking a significant milestone for Australia’s h...

December 11, 2024 | News

Actinogen Expands Alzheimer’s Trial Across Australia and US, Eyes Interim Results in 2025

Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial Officer, Andrew Udell X...

December 10, 2024 | News

Skyhawk Therapeutics Gains Australian Approval to Extend SKY-0515 Huntington’s Disease Trial to 12 Weeks

Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Hun...

December 10, 2024 | News

ShiraTronics Launches Pivotal RELIEV-CM2 Trial with First Neuromodulation Implants for Chronic Migraine in the U.S. and Australia

First Implants of Innovative Device Completed in the United States and Australia ShiraTronics, a clinical-stage innovator in neuromodulatio...

December 04, 2024 | News

QIAGEN’s QIAcuityDx Digital PCR System Approved by ARTG to Enhance Clinical Diagnostics Across Australia and New Zealand

Provides absolute quantitation, essential for precise monitoring of low-abundance targets in clinical diagnostics Enhances lab effic...

November 26, 2024 | News

Vaxxas Expands Global Patent Portfolio to 42, Securing Exclusive Rights to HD-MAP Vaccination Technology

-Vaxxas, a clinical-stage biotechnology company, has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to m...

November 25, 2024 | News

Philips and Edith Cowan University Forge Strategic Partnership to Elevate Clinical Ultrasound Training in APAC

Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Edith Cowan University Australia (ECU) announced a new strategic p...

November 20, 2024 | News

Telix Pharmaceuticals Expands Theranostic Pipeline with Novel FAP-Targeting Radiopharmaceuticals

Telix Pharmaceuticals Limited announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the m...

November 19, 2024 | News

Perth’s Lixa Kicks Off Clinical Trial for NeoX-101, Aiming to Combat Chronic Lung Infections

Lixa, a Perth-based biotechnology company, has announced the launch of its first clinical trial to evaluate the safety and tolerability of NeoX-101, an inn...

November 14, 2024 | News

Australia’s Aravax Establishes UK Subsidiary to Advance Allergy Immunotherapies

Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies designed to be safe, convenient, and precisely targeted, today an...

November 14, 2024 | News

Australia’s Neurizon Therapeutics Secures Positive EMA Opinion for Orphan Medicinal Product Designation of NUZ-001 in ALS

Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral S...

November 12, 2024 | News

Stay Connected